6B-001
65Bio lead product is 6B-001 an orally available small molecule found to be well tolerated in human. 6B-001 is in preclinical development phase for the treatment of auditory pathologies. The initial focus is on the treatment of chronic tinnitus and the longer-term focus is on hearing loss and vertigo. Tinnitus is the perception of noise or ringing in the ears. The noise can be intermittent or continuous, and can vary in loudness. It affects about 10-15% percent of people and in 1–2% of the population the condition is disabling i.e. interferes with concentration and causes anxiety and depression. Tinnitus is usually associated with some degree of hearing loss. Prolonged exposure to loud sounds is the most common cause of tinnitus. The available pharmacological therapies for tinnitus are limited and/or suboptimal.
Pe-clinical stage. Undisclosed.
6B-002